Branea I, Gaiţă D, Drăgulescu I, Socoteanu I, Luca C, Mancaş S, Drăgan S, Iurciuc M, Velimirovici D, Gaşpar M, Fluture A, Ionac A, Deutsch P, Pescariu S, Petrescu L, Branea H, Mut B, Dină C, Crâsnic M, Sarău C A
Clinic of Cardiac Rehabilitation, Institute of Cardiology Timişoara.
Rom J Intern Med. 1999 Jul-Sep;37(3):287-96.
The benefit of the treatment with magnesium orotate (magnerot) was assessed in a randomised, single blind and placebo controlled study. Respecting the inclusion criteria were selected 32 patients with ischemia chronic failure in early postoperative period after CABG. The main improvements induced by magnesium orotate are the increase in exercise capacity (distance ambulated during 6 minutes walk test and ergospirometric parameters) and the reduction of ventricular premature beats. The treatment was well tolerated and the adverse reactions were not significant. The study strongly suggests the benefit of magnesium orotate added to classical antiischemic therapy in the complex management of coronary patients after CABG.
在一项随机、单盲、安慰剂对照研究中评估了乳清酸镁（马格诺罗）治疗的益处。符合纳入标准的32例冠状动脉旁路移植术（CABG）术后早期慢性缺血性心力衰竭患者被选入研究。乳清酸镁带来的主要改善包括运动能力的提高（6分钟步行试验中的行走距离和运动肺量计参数）以及室性早搏的减少。该治疗耐受性良好，不良反应不显著。该研究有力地表明，在CABG术后冠心病患者的综合管理中，在经典抗缺血治疗基础上加用乳清酸镁有益。
